• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by TransMedics Group Inc.

    4/10/26 7:50:57 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TMDX alert in real time by email
    DEFA14A 1 d88080ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    TRANSMEDICS GROUP, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    Your Vote Counts!
    TRANSMEDICS GROUP, INC.
    2026 Annual Meeting Vote by May 19, 2026
    11:59 PM ET
    TRANSMEDICS GROUP, INC.200 MINUTEMAN ROAD, SUITE 302ANDOVER, MA 01810
    V94188-P45932
    You invested in TRANSMEDICS GROUP, INC. and it’s time to vote!
    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 20, 2026.
    Get informed before you vote
    View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 6, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.For complete information and to vote, visit www.ProxyVote.comControl #
    For complete information and to vote, visit www.ProxyVote.com
    Control #
    Smartphone users
    Point your camera here and vote without entering a control number
    Vote Virtually at the Meeting*
    May 20, 2026
    8:00 A.M. Eastern Time
    Virtually at:www.virtualshareholdermeeting.com/TMDX2026
    *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com
    THIS IS NOT A VOTABLE BALLOT
    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.
    Board Recommends
    Voting Items
    1. Election of Directors
    Nominees:
    1a. Waleed H. Hassanein, M.D. For
    1b. James R. Tobin For
    1c. Edward M. Basile For
    1d. Thomas J. Gunderson For
    1e. Edwin M. Kania, Jr. For
    1f. Stephanie Lovell For
    1g. Merilee Raines For
    1h. David Weill, M.D. For
    2. To approve, on a non-binding advisory basis, the compensation paid to TransMedics’ named executive officers. For
    3. To approve an amendment to the TransMedics Group, Inc. Amended and Restated 2019 Stock Incentive Plan to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the TransMedics Group, Inc. Amended and Restated 2019 Stock Incentive Plan by 2,750,000 shares and make certain other changes as set forth in the proxy statement. For
    4. To ratify the appointment of PricewaterhouseCoopers LLP as TransMedics Group, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For
    NOTE: Such other business as may properly come before the meeting or any adjournment thereof.
    Prefer to receive an email instead? White voting on www.ProxyVote.com, be sure to click “Delivery Setting”.
    V94189-P45932

    Get the next $TMDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMDX

    DatePrice TargetRatingAnalyst
    10/23/2025$148.00Hold → Buy
    Needham
    10/13/2025$145.00Buy
    Jefferies
    9/16/2025$155.00Outperform
    Evercore ISI
    9/4/2025$115.00Hold
    Stifel
    12/17/2024$116.00 → $75.00Overweight → Neutral
    Analyst
    11/22/2024Buy → Hold
    Needham
    10/29/2024$200.00 → $125.00Outperform
    Oppenheimer
    10/29/2024$208.00 → $109.00Buy
    Needham
    More analyst ratings

    $TMDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hassanein Waleed H bought $1,000,350 worth of shares (8,775 units at $114.00) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    11/18/25 4:30:07 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President & CEO Hassanein Waleed H bought $1,982,121 worth of shares (16,875 units at $117.46) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    8/8/25 4:30:13 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

    ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025. As previously disclosed, in the fourth quarter of 2025, TransMedics released a $103.3 million U.S. tax valuation allowance, which drove recognition of a

    2/27/26 7:00:00 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

    ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m

    2/24/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089 shares of its common stock and an aggregate of 26,549 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 16,734 shares of TransMedics' common stock and 11,082 restricted stock units granted to Giovanni Cecere, the

    2/20/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    SEC Filings

    View All

    SEC Form DEFA14A filed by TransMedics Group Inc.

    DEFA14A - TransMedics Group, Inc. (0001756262) (Filer)

    4/10/26 7:50:57 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by TransMedics Group Inc.

    DEF 14A - TransMedics Group, Inc. (0001756262) (Filer)

    4/10/26 7:48:35 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.

    SCHEDULE 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

    3/27/26 1:34:36 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TransMedics Group upgraded by Needham with a new price target

    Needham upgraded TransMedics Group from Hold to Buy and set a new price target of $148.00

    10/23/25 7:00:10 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on TransMedics Group with a new price target

    Jefferies initiated coverage of TransMedics Group with a rating of Buy and set a new price target of $145.00

    10/13/25 8:59:30 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Evercore ISI initiated coverage on TransMedics Group with a new price target

    Evercore ISI initiated coverage of TransMedics Group with a rating of Outperform and set a new price target of $155.00

    9/16/25 8:11:09 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Forsyth Matthew S.

    3 - TransMedics Group, Inc. (0001756262) (Issuer)

    3/13/26 5:30:14 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lovell Stephanie sold $178,497 worth of shares (1,193 units at $149.62), decreasing direct ownership by 29% to 2,866 units (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    3/6/26 6:12:58 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Weill David exercised 3,571 shares at a strike of $14.20 and sold $524,294 worth of shares (3,571 units at $146.82) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    3/6/26 6:09:13 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    Leadership Updates

    Live Leadership Updates

    View All

    TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

    ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

    12/2/24 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

    NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

    9/26/24 6:04:00 PM ET
    $CCRN
    $CHK
    $ENSG
    Professional Services
    Consumer Discretionary
    Oil & Gas Production
    Energy

    TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

    ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be

    7/26/23 5:09:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    Financials

    Live finance-specific insights

    View All

    TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

    ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m

    2/24/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 7

    2/10/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TransMedics Reports Third Quarter 2025 Financial Results

    ANDOVER, Mass., Oct. 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $143.8 million in the third quarter of 2025, a 32% increase compared to the third quarter of 2024Generated net income of $24.3 million or $0.66 per diluted share in the third quarter of 2025Owned 21 aircraft as of September 30, 2025; own

    10/29/25 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

    SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

    10/7/24 11:37:08 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

    SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

    10/4/24 4:23:23 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by TransMedics Group Inc. (Amendment)

    SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

    2/14/24 6:28:57 AM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care